-

11:21:02 AM

AXIM Stock News

AXIM - Axim Biotechnologies Inc

07/26/22 9:00 AM

OTC : AXIM

AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launched an enhanced version of its rapid Ocular

RHEA-AI

neutral

07/21/22 9:00 AM

OTC : AXIM

AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been featured on the Vision is More

RHEA-AI

neutral

07/12/22 9:00 AM

OTC : AXIM

covid-19

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State University (ASU) entitled, “ Third

RHEA-AI

neutral

06/02/22 9:00 AM

OTC : AXIM

AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide

RHEA-AI

neutral

05/24/22 9:00 AM

OTC : AXIM

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the optimization of a rapid

RHEA-AI

neutral

05/10/22 9:00 AM

OTC : AXIM

AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

AXIM Biotechnologies, Inc ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample collector system and has filed

RHEA-AI

positive

04/27/22 9:00 AM

OTC : AXIM

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for

RHEA-AI

neutral

04/19/22 8:30 AM

OTC : AXIM

AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED management team Supply agreements in

RHEA-AI

positive

03/08/22 9:00 AM

OTC : AXIM

AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease

AXIM Biotechnologies, Inc ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid quantitative tear test for

RHEA-AI

neutral

03/07/22 9:00 AM

OTC : AXIM

covid-19

AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its focus for its rapid COVID-19 Neutralizing

RHEA-AI

neutral